| Outcome Measures: |
Primary: Number of subjects with adverse events after ascending single or titrated mulitple subcutaneous doses of GSK2374697, Adverse events, laboratory parameters, ECGs, and vital signs, up to 70 days post dose|pharmacokinetic parameters of GSK2374697, after ascending single or titrated multiple subcutaneous doses, in healthy subjects, Pharmacokinetics parameters: AUCs, Cmax, tmax, elimination half-life (t½), lag time (tlag), apparent clearance (CL/F) and apparent volume of distribution (V/F), area under the plasma drug concentration versus time curve on Days 1 through end of study (up to 70 Days), pre-dose, then 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, and 66 hours after dose (this schedule is q6h through Day 3, up to just prior to Day 4). In addition, sampling continues out through Day 70, on specific days, q12h. | Secondary: pharmacodynamic effects of GSK2374697 in healthy subjects after meal challenge, Fasting, 2h, and Cmax parameters on Day -1 and approximately Day 6 (or Day 16), On 2 days|dose proportionality of GSK2374697, Pharmacokinetics parameters based on single and/or titrated multiple subcutaneous doses of GSK2374697, up to 70 days post dose
|
